Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial
    Meeting Abstract

    Chaft, J. E.; Swanson, S.; Lee, J. M.; Lin, J.; Tsukada, H.; Li, T.; Ripley, R. T.; Kaifi, J. T.; Baik, C. S.; Bunn, P. A. Jr.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Bouattour, M.; Cheng, A. L.; Dayyani, F.; Khalil, D.; Li, D.; Liao, C. Y.; LoĢpez, C. L.; Rimassa, L.; Deutsch, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer
    Meeting Abstract

    Mayer, E. L.; Jhaveri, K. L.; Hamilton, E. P.; Kalinsky, K.; Constanzo, J. D.; Rosenthal, K. M.; Spring, L.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Treatment patterns among HCPs and concordance with expert recommendations in HER2-negative early breast cancer: Analysis of an interactive online treatment decision support tool
    Meeting Abstract

    Brandt, K. G.; Becker, M. N.; Gupta, T.; Kalinsky, K.; Spring, L.; Traina, T. A.; Yardley, D. A.; Rosenthal, K. M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting fitness for chemotherapy in older adults with metastatic bladder cancer
    Meeting Abstract

    Russell, B.; Fein, D. E. C.; Berg, S. A.; Gupta, S.; Rosenberg, J. E.; Choueiri, T. K.; Bellmunt, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma
    Meeting Abstract

    Falchi, L.; Walker, P.; Presgrave, P.; Gregory, G. P.; Marie, D.; Leyco, A. J.; Demaria, O.; Le Floch, F.; Hanekom, W.; Bonin, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, L.; Wei, Y.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
    Meeting Abstract

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save